RGNX
7:10 AM
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting
Trial Results • Phase 3Topline results Thu, May 14, 2026regenxbio.com